All Eyes On Prelude Therapeutics

From: Delaware Business Times

“Discovery is an art,” Vaddi says. “It’s not something that’s taught.”

As Vaddi’s latest business venture, Prelude Therapeutics, finds its way forward, he hopes to be in the middle of a variety of exciting breakthroughs. As a former member of DuPont Pharmaceuticals and a founding father of Wilmington-based Incyte, Vaddi has developed a reputation for cultivating ideas and helping to bring them to market.

At Prelude, Vaddi hopes to replicate the successes he had in other laboratory settings by creating novel therapies that are able to treat particularly virulent cancers and other rare diseases. The 10-person company, started earlier this year with seed money from “two of the world’s top venture capitalists who fund biotechs,” according to Vaddi, has set up shop at the University of Delaware’s STAR Campus and has already built collaborative relationships with some of the nation’s top hospitals.

The process of taking a therapy from concept to marketplace appeals to Vaddi, but his true passion comes from the early stages of development.

“If I am asked what is the most rewarding thing I did during my 14 years at Incyte, it was going to the laboratory every day, looking at the data, looking at the ideas and brainstorming ideas to move them forward.” Read More

No Comments Yet.

Leave your comments